DE60226446D1 - Zusammensetzungen zur behandlung von neoplastischen krankheiten welche einen cyanoguanidine ikk inhibitor und ein zweites antineoplastisches arzneimittel enthalten - Google Patents
Zusammensetzungen zur behandlung von neoplastischen krankheiten welche einen cyanoguanidine ikk inhibitor und ein zweites antineoplastisches arzneimittel enthaltenInfo
- Publication number
- DE60226446D1 DE60226446D1 DE60226446T DE60226446T DE60226446D1 DE 60226446 D1 DE60226446 D1 DE 60226446D1 DE 60226446 T DE60226446 T DE 60226446T DE 60226446 T DE60226446 T DE 60226446T DE 60226446 D1 DE60226446 D1 DE 60226446D1
- Authority
- DE
- Germany
- Prior art keywords
- alkoxycarbonyl
- alkoxy
- amino
- compositions
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003458 I kappa b kinase inhibitor Substances 0.000 title abstract 2
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000118 anti-neoplastic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 title 1
- -1 nitro, sulfo, cyano, amino Chemical group 0.000 abstract 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000005518 carboxamido group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29292801P | 2001-05-24 | 2001-05-24 | |
| PCT/DK2002/000351 WO2002094322A2 (en) | 2001-05-24 | 2002-05-24 | Combination medicament for treatment of neoplastic diseases containing cyanoguanidine ikk inhibitors and a second anti-neoplastic drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60226446D1 true DE60226446D1 (de) | 2008-06-19 |
Family
ID=23126850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60226446T Expired - Fee Related DE60226446D1 (de) | 2001-05-24 | 2002-05-24 | Zusammensetzungen zur behandlung von neoplastischen krankheiten welche einen cyanoguanidine ikk inhibitor und ein zweites antineoplastisches arzneimittel enthalten |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20030045515A1 (enExample) |
| EP (1) | EP1411984B1 (enExample) |
| JP (1) | JP2005508857A (enExample) |
| KR (1) | KR20040007607A (enExample) |
| CN (1) | CN1516600A (enExample) |
| AT (1) | ATE394100T1 (enExample) |
| AU (1) | AU2002316795B2 (enExample) |
| BR (1) | BR0209936A (enExample) |
| CA (1) | CA2449442A1 (enExample) |
| CZ (1) | CZ20033189A3 (enExample) |
| DE (1) | DE60226446D1 (enExample) |
| HU (1) | HUP0400024A3 (enExample) |
| IL (1) | IL158821A0 (enExample) |
| MX (1) | MXPA03010691A (enExample) |
| PL (1) | PL366462A1 (enExample) |
| RU (1) | RU2291710C2 (enExample) |
| WO (1) | WO2002094322A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7253193B2 (en) * | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| PL228742B1 (pl) * | 2002-05-17 | 2018-05-30 | Leo Pharma As | Proleki cyjanoguanidynowe, kompozycja farmaceutyczna zawierająca te proleki oraz związki pośrednie |
| WO2003097602A1 (en) * | 2002-05-17 | 2003-11-27 | Leo Pharma A/S | Cyanoguanidine produgs |
| EP1556053A4 (en) | 2002-10-31 | 2006-04-19 | Amgen Inc | ANTI-INFLAMMATORY AGENTS |
| US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
| WO2004047673A2 (en) * | 2002-11-21 | 2004-06-10 | Novacea, Inc. | Treatment of liver disease with active vitamin d compounds |
| US20050075341A1 (en) * | 2003-07-17 | 2005-04-07 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury |
| TW200616967A (en) | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
| TW200626142A (en) | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| US8053446B2 (en) * | 2004-12-22 | 2011-11-08 | Leo Pharma A/S | Cyanoguanidine compounds |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| NZ563687A (en) | 2005-06-30 | 2011-07-29 | Smithkline Beecham Corp | 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide for inhibiting IKK2 (aka IKKbeta) |
| EP1912646A2 (de) * | 2005-08-04 | 2008-04-23 | Bayer HealthCare AG | KOMBINATIONEN MIT IKK-ß INHIBITOREN |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| WO2009132050A2 (en) | 2008-04-21 | 2009-10-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| WO2010088842A1 (zh) * | 2009-02-06 | 2010-08-12 | 天津和美生物技术有限公司 | 含有吡啶基氰基胍的药物组合物及其制备和应用 |
| US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
| AR082886A1 (es) | 2010-09-03 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones farmaceuticas que los contienen |
| CN108779073A (zh) * | 2015-06-23 | 2018-11-09 | 凯斯西储大学 | 用于治疗癌症的组合物和方法 |
| EP3478269A4 (en) | 2016-06-29 | 2020-04-08 | Otonomy, Inc. | OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9219472D0 (en) * | 1992-09-15 | 1992-10-28 | Leo Pharm Prod Ltd | Chemical compounds |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| HU225415B1 (en) * | 1996-07-15 | 2006-11-28 | Sankyo Co | Medicinal compositions comprising cs-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma |
| GB9711119D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711124D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711123D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711125D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711122D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| AU1494702A (en) * | 2000-11-21 | 2002-06-03 | Leo Pharma As | Cyanoguanidine prodrugs |
-
2002
- 2002-05-21 US US10/151,094 patent/US20030045515A1/en not_active Abandoned
- 2002-05-24 CN CNA028121880A patent/CN1516600A/zh active Pending
- 2002-05-24 JP JP2002591038A patent/JP2005508857A/ja not_active Withdrawn
- 2002-05-24 MX MXPA03010691A patent/MXPA03010691A/es unknown
- 2002-05-24 AU AU2002316795A patent/AU2002316795B2/en not_active Ceased
- 2002-05-24 CZ CZ20033189A patent/CZ20033189A3/cs unknown
- 2002-05-24 DE DE60226446T patent/DE60226446D1/de not_active Expired - Fee Related
- 2002-05-24 RU RU2003137006/15A patent/RU2291710C2/ru not_active IP Right Cessation
- 2002-05-24 KR KR10-2003-7015363A patent/KR20040007607A/ko not_active Ceased
- 2002-05-24 BR BR0209936-5A patent/BR0209936A/pt not_active IP Right Cessation
- 2002-05-24 PL PL02366462A patent/PL366462A1/xx not_active Application Discontinuation
- 2002-05-24 EP EP02745167A patent/EP1411984B1/en not_active Expired - Lifetime
- 2002-05-24 CA CA002449442A patent/CA2449442A1/en not_active Abandoned
- 2002-05-24 HU HU0400024A patent/HUP0400024A3/hu unknown
- 2002-05-24 WO PCT/DK2002/000351 patent/WO2002094322A2/en not_active Ceased
- 2002-05-24 IL IL15882102A patent/IL158821A0/xx unknown
- 2002-05-24 AT AT02745167T patent/ATE394100T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0209936A (pt) | 2004-04-06 |
| JP2005508857A (ja) | 2005-04-07 |
| CZ20033189A3 (cs) | 2004-12-15 |
| MXPA03010691A (es) | 2004-07-01 |
| CA2449442A1 (en) | 2002-11-28 |
| RU2003137006A (ru) | 2005-04-10 |
| HUP0400024A3 (en) | 2007-05-29 |
| AU2002316795B2 (en) | 2007-08-02 |
| EP1411984A2 (en) | 2004-04-28 |
| PL366462A1 (en) | 2005-02-07 |
| WO2002094322A3 (en) | 2004-02-26 |
| WO2002094322A2 (en) | 2002-11-28 |
| HUP0400024A2 (hu) | 2004-04-28 |
| US20030045515A1 (en) | 2003-03-06 |
| RU2291710C2 (ru) | 2007-01-20 |
| KR20040007607A (ko) | 2004-01-24 |
| EP1411984B1 (en) | 2008-05-07 |
| ATE394100T1 (de) | 2008-05-15 |
| CN1516600A (zh) | 2004-07-28 |
| IL158821A0 (en) | 2004-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE394100T1 (de) | Zusammensetzungen zur behandlung von neoplastischen krankheiten welche einen cyanoguanidine ikk inhibitor und ein zweites antineoplastisches arzneimittel enthalten | |
| DK0705254T3 (da) | Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer | |
| WO2003091259A8 (en) | Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors | |
| AR049662A1 (es) | Derivados de 1,3-fenilendiamina con efecto inhibitorio de b-raf; un metodo para su preparacion, composiciones farmaceuticas que los contienen y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer | |
| TR199801151T2 (xx) | Trombin inhibit�r� �n ila�lar. | |
| AR039257A1 (es) | Derivados de benzamida | |
| AR053992A1 (es) | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. | |
| DK0778834T3 (da) | Bicykliske, heterocykliske diarylforbindelser som inhibitorer af cyclooxygenase-2 | |
| DK1163212T3 (da) | Amidderivater | |
| RU95106996A (ru) | Сульфонилалканоиламино-гидроксиэтиламино-сульфонамидные соединения, фармацевтические композиции и способы лечения и ингибирования ретровирусных протеаз | |
| TR200001279T2 (tr) | Poli (ADP-riboz) polimeraz ("PARP") inhibitörleri, nevral ve kardiyovasküler doku hasarının tedavisi için yöntemler ve farmasötik bileşimler. | |
| ES2181614T3 (es) | Sulfonilfenilheterociclos sustituidos como inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa. | |
| AR039127A1 (es) | Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento | |
| WO2002034753A3 (en) | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | |
| AR032136A1 (es) | Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas | |
| ATE362912T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| AR029635A1 (es) | Compuesto derivado de una piridona policiclica sustituida, composicion farmaceutica que lo comprende y el uso de dicho compuesto y de dicha composicion en la fabricacion de medicamentos utiles para la inhibicion selectiva de la cascada de coagulacion | |
| ATE277897T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| DE69615555D1 (de) | 6-carboxamido-dihydropyran-derivate | |
| ATE278663T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| DK1608655T3 (da) | Pyrroloimidazolderivater, fremstillingen deraf, farmaceutiske præparater indeholdende disse og anvendelse deraf som nootrope midler | |
| UY26895A1 (es) | Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2 | |
| EP1453506A4 (en) | Topoisomerase GIFT FUNDS | |
| AR030940A1 (es) | Derivados de pirimidina, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la elaboracion de medicamentos | |
| ATE469148T1 (de) | Zur behandlung von mit trpv1 in zusammenhang stehenden erkrankungen geeignete 2-(benzimidazol- 1yl)-n-(4-phenylthiazol-2-yl)acetamidderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8339 | Ceased/non-payment of the annual fee |